The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinsons disease, Parkinsons disease dementia (PDD), or Huntingtons disease, and those associated with striatal hypofunction or basal ganglia dysfunction.